ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1601

Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial

Michaela Koehm1, Ann Christina Foldenauer2, Tanja Rossmanith3, Herbert Kellner4, Uta Kiltz5, Juergen Rech6, Gerd Burmester7, David Kofler8, Jan Brandt-Juergens9, Stephanie Finzel10, Raoul Bergner11, Maren Sieburg12 and Frank Behrens13, 1Rheumatology Goethe-University Frankfurt, Frankfurt Am Main, Germany, 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, 3Fraunhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt, Germany, 4Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6University Clinic Erlangen, Erlangen, Germany, 7Charité University Medicine Berlin, Berlin, Germany, 8University of Cologne, Cologne, Germany, 9Rheumatologische Schwerpunktpraxis, Berlin, Germany, 10University of Freiburg, Freiburg, Germany, 11Klinikum Ludwigshafen, Ludwigshafen, Germany, 12Rheumatologische Facharztpraxis, Magdeburg, Germany, 13Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany

Meeting: ACR Convergence 2022

Keywords: gender, Psoriatic arthritis, Spondyloarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Spondyloarthritis Including PsA – Treatment II: PsA

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Subgroup analysis from different clinical trials and real-world data suggest, that there are differences in baseline characteristics, clinical phenotypes, and treatment responses in female patients compared to males. Especially in psoriatic arthritis, which is a heterogeneous disease, only little is known about gender differences. We conducted an investigator-initiated, randomized, placebo-controlled trial (IIT) in active PsA to examine if outcomes of treatment with ustekinumab (UST) in combination with MTX (either newly initiated or ongoing) were different from UST only (+Placebo; PBO). We used this data to investigate gender differences in focus on baseline characteristics and treatment responses to UST only and to UST+MTX combinational therapy.

Methods: A total of 186 patients with active PsA (defined as TJC >/=4, SJC >/=4 [68/66 joint count] and DAS28 >/=3.2) were screened for eligibility. 173 patients were randomized to UST+MTX (new or ongoing) or UST+PBO. 166 patients (mITT population) were included in this subgroup analysis. Patients were stratified according to gender. Demographic data and disease activity status (joint count [TJC/SJC], enthesitis [LEI], dactylitis count, PASI, BSA), QoL (EQ5D, DLQI), and function (HAQ) were compared between the groups. Response rates (pain response, ACR response) were evaluated at week 24.

Results: Of the 166 patients included in this subgroup analysis, 41,6% were female. Demographic data including years since the onset of PsA, age, and BMI were well balanced between the groups. Skin involvement (BSA, PASI) was higher in the groups of UST+MTX treatment, especially in the female group with a BSA of 9.6% and PASI of 5.3. Enthesitis was more frequent in the female groups whereas dactylitis was more prominent in the male groups. Other disease activity features such as DAS28, DAPSA, TJC [68], SJC [66], and pain (VAS 100) showed comparable levels at baseline (table 1). Treatment response features are shown in Figures 1 and 2. Differences are found between the male and female groups, especially in the resolution of enthesitis, dactylitis, and pain. With a focus on pain reduction and ACR response rates, higher levels of reduction are achieved in the male groups compared to females. Here, the UST+MTX therapy shows less difference from baseline in the achievement of treatment responses whereas male patients have a higher improvement for resolution of enthesitis and dactylitis by combining UST+MTX compared to baseline.

Conclusion: Data from an RCT was analyzed in focus on gender differences in baseline characteristics and treatment responses to UST+MTX or UST-only therapy over 24-weeks. In comparison to the male cohort, females show a decreased response in the resolution of pain, enthesitis, dactylitis, and ACR response rates. Different from males, females seem not to benefit from a UST+MTX combinational treatment for the improvement of enthesitis and dactylitis.

Supporting image 1

Table 1: Baseline Characteristics between the treatment groups.

Supporting image 2

Figure 1: Differences (BL-W24) in the disease activity pattern compared between the male and female group and between the treatment strategies (UST+MTX or UST only).

Supporting image 3

Figure 2: Differences in response rates to pain and ACR response between male and female and the treatment groups (UST+MTX or UST only).


Disclosures: M. Koehm, Janssen; A. Foldenauer, Janssen; T. Rossmanith, Janssen; H. Kellner, Merck/MSD; U. Kiltz, AbbVie, Amgen, Biogen, Fresenius, GSK, Hexal, Novartis, Pfizer, Biocad, Lilly, Grünenthal, Janssen, MSD, Roche, UCB; J. Rech, Novartis, SOBI, AbbVie/Abbott, Biogen, Bristol-Myers Squibb(BMS), Chugai, GlaxoSmithKlein(GSK), Janssen, Eli Lilly, Merck/MSD, Mylan, Roche, Sanofi, UCB; G. Burmester, AbbVie, Galapagos, Lilly, MSD, Pfizer, Roche, UCB, Janssen, Gilead Sciences, Inc.; D. Kofler, None; J. Brandt-Juergens, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Janssen, Eli Lilly, Merck/MSD, Novartis, Pfizer, Roche, UCB, Sanofi-Aventis, Medac, Gilead, Gilead, Affibody; S. Finzel, None; R. Bergner, None; M. Sieburg, None; F. Behrens, AbbVie, Boehringer Ingelheim, Celgene, Chugai, Eli Lilly, Genzyme, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi, Bristol-Myers Squibb(BMS), Galapagos, Gilead, UCB, Affibody, MoonLake, GlaxoSmithKlein(GSK).

To cite this abstract in AMA style:

Koehm M, Foldenauer A, Rossmanith T, Kellner H, Kiltz U, Rech J, Burmester G, Kofler D, Brandt-Juergens J, Finzel S, Bergner R, Sieburg M, Behrens F. Female Psoriatic Arthritis Patients Show Differences in Treatment Response to IL12/23 Inhibition in Combination with or Without MTX Compared to Male – Results from a Multicenter Investigator-initiated Randomized Placebo-controlled Clinical Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/female-psoriatic-arthritis-patients-show-differences-in-treatment-response-to-il12-23-inhibition-in-combination-with-or-without-mtx-compared-to-male-results-from-a-multicenter-investigator-i/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/female-psoriatic-arthritis-patients-show-differences-in-treatment-response-to-il12-23-inhibition-in-combination-with-or-without-mtx-compared-to-male-results-from-a-multicenter-investigator-i/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology